TGFβ2-铁调素正反馈环路在小梁网中提示铁参与青光眼病理
本研究探索TGF-β2是否通过上调铁调素参与原发性开角型青光眼(POAG)发病。在人类小梁网细胞及人/牛眼前段器官培养中发现,TGF-β2上调铁调素,铁调素下调膜铁转运蛋白,增加铁蛋白和铁催化的活性氧(ROS),进而反向上调TGF-β2,形成正反馈环路;肝素和N-乙酰肌肽可部分阻断该环路。
要点
- TGF-β2上调小梁网局部铁调素,铁调素下调膜铁转运蛋白,增加铁蛋白和ROS。
- 铁催化的ROS反向上调TGF-β2,形成自我维持的正反馈环路。
- 肝素和N-乙酰肌肽可部分阻断TGF-β2介导的环路,提示铁和ROS参与POAG。
核心结论
- TGF-β2与铁调素通过铁催化的ROS形成自我维持的正反馈环路,提示铁和ROS参与TGF-β2介导的POAG。
研究设计与样本
- 研究使用原代人小梁网细胞以及人和牛离体眼前段器官培养,暴露于生物活性TGF-β2、铁调素、肝素或N-乙酰肌肽。
- 通过半定量RT-PCR、Western blotting和免疫组化评估铁调素、膜铁转运蛋白、铁蛋白和TGF-β2表达,用二氢乙啶定量ROS增加。
主要发现
- 原代人小梁网细胞和牛小梁网组织局部合成铁调素,并被生物活性TGF-β2上调。
- 铁调素下调其下游靶点膜铁转运蛋白,增加铁蛋白和铁催化的ROS。
- 铁调素引起TGF-β2在转录和翻译水平反向上调。
- 肝素下调铁调素,减少TGF-β2介导的铁蛋白和ROS增加。
- 肝素和N-乙酰肌肽均减少TGF-β2介导的TGF-β2反向上调。
临床怎么用
- 提示改造现有铁调素拮抗剂用于眼部,可能对TGF-β2相关POAG的治疗管理有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Elevated levels of transforming-growth-factor (TGF)-β2 in the trabecular meshwork (TM) and aqueous humor are associated with primary open-angle glaucoma (POAG). The underlying mechanism includes alteration of extracellular matrix homeostasis through Smad-dependent and independent signaling. Smad4, an essential co-Smad, upregulates hepcidin, the master regulator of iron homeostasis. Here, we explored whether TGF-β2 upregulates hepcidin, implicating iron in the pathogenesis of POAG. METHODS: Primary human TM cells and human and bovine ex vivo anterior segment organ cultures were exposed to bioactive TGF-β2, hepcidin, heparin (a hepcidin antagonist), or N-acetyl carnosine (an antioxidant), and the change in the expression of hepcidin, ferroportin, ferritin, and TGF-β2 was evaluated by semiquantitative RT-PCR, Western blotting, and immunohistochemistry. Increase in reactive oxygen species (ROS) was quantified with dihydroethidium, an ROS-sensitive dye. RESULTS: Primary human TM cells and bovine TM tissue synthesize hepcidin locally, which is upregulated by bioactive TGF-β2. Hepcidin downregulates ferroportin, its downstream target, increasing ferritin and iron-catalyzed ROS. This causes reciprocal upregulation of TGF-β2 at the transcriptional and translational levels. Heparin downregulates hepcidin, and reduces TGF-β2-mediated increase in ferritin and ROS. Notably, both heparin and N-acetyl carnosine reduce TGF-β2-mediated reciprocal upregulation of TGF-β2. CONCLUSIONS: The above observations suggest that TGF-β2 and hepcidin form a self-sustained feed-forward loop through iron-catalyzed ROS. This loop is partially disrupted by a hepcidin antagonist and an anti-oxidant, implicating iron and ROS in TGF-β2-mediated POAG. We propose that modification of currently available hepcidin antagonists for ocular use may prove beneficial for the therapeutic management of TGF-β2-associated POAG.
引用
- Ashok A, Chaudhary S, Kritikos AE, et al. TGFβ2-Hepcidin Feed-Forward Loop in the Trabecular Meshwork Implicates Iron in Glaucomatous Pathology. Invest Ophthalmol Vis Sci. 2020. PMID: 32182331. doi:10.1167/iovs.61.3.24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。